Study of Efficacy and Safety of Twice Daily Oral Iptacopan (LNP023) in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy

NCT04820530 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Interventions

DRUG: Iptacopan (LNP023)

Sponsor

Novartis Pharmaceuticals